Future Fund LLC Buys 6,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Future Fund LLC grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 58.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,596 shares of the biopharmaceutical company’s stock after acquiring an additional 6,500 shares during the period. Halozyme Therapeutics comprises 2.4% of Future Fund LLC’s investment portfolio, making the stock its 20th biggest position. Future Fund LLC’s holdings in Halozyme Therapeutics were worth $841,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Parkside Financial Bank & Trust boosted its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Halozyme Therapeutics by 173.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,028 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Trading Up 1.4 %

Shares of HALO opened at $60.98 on Monday. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a market capitalization of $7.51 billion, a P/E ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm’s 50 day simple moving average is $55.70 and its 200 day simple moving average is $54.73.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 over the last 90 days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.